Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and preliminary efficacy of olaparib and
vorinostat when used together in participants with relapsed/refractory and or metastatic
breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Jenny C. Chang, MD The Methodist Hospital Research Institute